KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy
Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.
Comments from KORTUC
“We are pleased to share our vision with and receive such strong support from our new investor as we are accelerating our clinical research in the UK and the US to bring to cancer patients globally a product that can make a true difference in the near future – we firmly believe that Kortuc radiosensitizer can change the paradigm for use of radiotherapy across cancer types and stages” highlighted Kazu Matsuda, Chief Executive Officer of KORTUC.
Comments from AXA Japan
“As a worldwide leader in insurance and asset management, our purpose is to act for human progress by protecting what matters. As new cancer patient growth accelerates, this investment illustrates our purpose to support innovative technologies that can serve humanity.” Jean-Baptiste Tricot, Director, Executive Officer and Chief Financial Officer of AXA Japan commented.
Boris Moutier, Corporate Officer of AXA Japan, Japan and Asia Chief Investment Officer, also highlights that “With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in cancer treatment field, and we are glad to engage in this greatly promising journey. Aligned with AXA Group’s vision, AXA Japan pursues investments into startups that may create innovations and produce tangible results.”
About KORTUC Inc.
KORTUC Inc is a clinical-stage biopharmaceutical company headquartered in Tokyo, Japan. KORTUC’s Pivotal Phase II Study is currently ongoing in the UK with Royal Marsden Hospital and a number of cancer centers*1 across the UK focusing on locally advanced, recurrent breast cancer. Phase I study was completed in 2019 successfully demonstrating the product’s safety and efficacy, while related publication was accepted by Red Journal (ASTRO) in June 2020.
About AXA Japan
AXA Japan is the Japanese arm of the AXA Group established in 1994. AXA Japan serves 2.64 million customers with 4.87 million policies by utilizing global expertise and experience of the AXA Group. Through partnerships with 511 Chambers of Commerce and Industry, private companies, and public offices across Japan, which have been built since the establishment of Nippon Dantai Life Insurance in 1934, AXA Japan offers a wide range of products, including death protection, medical/cancer protection, annuities, and asset accumulation, as well as advice on improving corporate welfare and Life Management®. In fiscal 2020, the company supported customers by paying 234.4 billion yen in claims and in annuity and maturity payouts.
About AXA Group
The AXA Group is a worldwide leader in insurance and asset management, with 153,000 employees serving 105 million clients in 54 countries. In 2020, IFRS revenues amounted to Euro 96.7 billion and underlying earnings to Euro 4.3 billion. AXA had Euro 1,032 billion in assets under management as of December 31, 2020. The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA). AXA’s American Depository Share is also quoted on the OTC QX platform under the ticker symbol AXAHY. The AXA Group is included in the main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD. It is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.
*1 Clinical sites for Pivotal Phase II study
- The Royal Marsden NHS Foundation Trust, London, UK
- University Hospitals of North Midlands, Stoke-on-Trent, UK
- Beatson West of Scotland Cancer Centre, Glasgow, UK
- The Christie NHS Foundation Trust, Manchester, UK
- Royal Cornwall Hospital NHS Trust, Truro, UK
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005431/en/
Contact information
KORTUC Inc.
Kazuhiko Tawara
+81 90 8813 6089
info@kortuc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom